aprinocarsen   Click here for help

GtoPdb Ligand ID: 14706

Synonyms: ISI 641A | ISIS 3521 | LY-900003 | LY900003 | PKC-ALPHA
Compound class: Nucleic acid
Comment: Aprinocarsen (ISIS 3521) is an antisense oligonucleotide (ASO) that is proposed to reduce the synthesis of protein kinase C-alpha (PKC-α) [1].
2D Structure
Click here for help
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CN([C@H]2C[C@@H]([C@@H](COP(=S)(O)O[C@H]3C[C@H](N4C=NC5=C4N=C(N)NC5=O)O[C@@H]3CO)O2)OP(=O)(OC[C@@H]6[C@H](C[C@H](N7C=C(C)C(=O)NC7=O)O6)OP(=S)(O)OC[C@@H]8[C@H](C[C@H](N9C=CC(=NC9=O)N)O8)OP(=S)(O)OC[C@@H]%10[C@H](C[C@H](N%11C=C(C)C(=O)NC%11=O)O%10)OP(=S)(O)OC[C@@H]%12[C@H](C[C@H](N%13C=CC(=NC%13=O)N)O%12)OP(=S)(O)OC[C@@H]%14[C@H](C[C@H](N%15C=NC%16=C%15N=C(N)NC%16=O)O%14)OP(=S)(O)OC[C@@H]%17[C@H](C[C@H](N%18C=CC(=NC%18=O)N)O%17)OP(=S)(O)OC[C@@H]%19[C@H](C[C@H](N%20C=C(C)C(=O)NC%20=O)O%19)OP(=S)(O)OC[C@@H]%21[C@H](C[C@H](N%22C=NC%23=C%22N=C(N)NC%23=O)O%21)OP(=S)(O)OC[C@@H]%24[C@H](C[C@H](N%25C=NC%26=C%25N=C(N)NC%26=O)O%24)OP(=S)(O)OC[C@@H]%27[C@H](C[C@H](N%28C=C(C)C(=O)NC%28=O)O%27)OP(=S)(O)OC[C@@H]%29[C@H](C[C@H](N%30C=NC%31=C%30N=C(N)NC%31=O)O%29)OP(=S)(O)OC[C@@H]%32[C@H](C[C@H](N%33C=NC%34=C%33N=CN=C%34N)O%32)OP(=S)(O)OC[C@@H]%35[C@H](C[C@H](N%36C=NC%37=C%36N=C(N)NC%37=O)O%35)OP(=S)(O)OC[C@@H]%38[C@H](C[C@H](N%39C=C(C)C(=O)NC%39=O)O%38)OP(=S)(O)OC[C@@H]%40[C@H](C[C@H](N%41C=C(C)C(=O)NC%41=O)O%40)OP(=S)(O)OC[C@@H]%42[C@H](C[C@H](N%43C=C(C)C(=O)NC%43=O)O%42)OP(=S)(O)OC[C@@H]%44[C@H](C[C@H](N%45C=CC(=NC%45=O)N)O%44)OP(=S)(O)OC[C@@H]%46[C@H](C[C@H](N%47C=NC%48=C%47N=CN=C%48N)O%46)O)S)C(=O)NC1=O
Isomeric SMILES CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(O[C@H]5C[C@@H](O[C@@H]5COP(=S)(O)O[C@H]6C[C@@H](O[C@@H]6CO)N7C=NC8=C7N=C(NC8=O)N)N9C=C(C(=O)NC9=O)C)S)N%10C=C(C(=O)NC%10=O)C)N%11C=CC(=NC%11=O)N)OP(=S)(O)OC[C@@H]%12[C@H](C[C@@H](O%12)N%13C=CC(=NC%13=O)N)OP(=S)(O)OC[C@@H]%14[C@H](C[C@@H](O%14)N%15C=NC%16=C%15N=C(NC%16=O)N)OP(=S)(O)OC[C@@H]%17[C@H](C[C@@H](O%17)N%18C=CC(=NC%18=O)N)OP(=S)(O)OC[C@@H]%19[C@H](C[C@@H](O%19)N%20C=C(C(=O)NC%20=O)C)OP(=S)(O)OC[C@@H]%21[C@H](C[C@@H](O%21)N%22C=NC%23=C%22N=C(NC%23=O)N)OP(=S)(O)OC[C@@H]%24[C@H](C[C@@H](O%24)N%25C=NC%26=C%25N=C(NC%26=O)N)OP(=S)(O)OC[C@@H]%27[C@H](C[C@@H](O%27)N%28C=C(C(=O)NC%28=O)C)OP(=S)(O)OC[C@@H]%29[C@H](C[C@@H](O%29)N%30C=NC%31=C%30N=C(NC%31=O)N)OP(=S)(O)OC[C@@H]%32[C@H](C[C@@H](O%32)N%33C=NC%34=C(N=CN=C%34%33)N)OP(=S)(O)OC[C@@H]%35[C@H](C[C@@H](O%35)N%36C=NC%37=C%36N=C(NC%37=O)N)OP(=S)(O)OC[C@@H]%38[C@H](C[C@@H](O%38)N%39C=C(C(=O)NC%39=O)C)OP(=S)(O)OC[C@@H]%40[C@H](C[C@@H](O%40)N%41C=C(C(=O)NC%41=O)C)OP(=S)(O)OC[C@@H]%42[C@H](C[C@@H](O%42)N%43C=C(C(=O)NC%43=O)C)OP(=S)(O)OC[C@@H]%44[C@H](C[C@@H](O%44)N%45C=CC(=NC%45=O)N)OP(=S)(O)OC[C@@H]%46[C@H](C[C@@H](O%46)N%47C=NC%48=C(N=CN=C%48%47)N)O
InChI InChI=1S/C196H249N68O105P19S19/c1-75-37-249(189(285)237-165(75)267)132-23-89(109(337-132)51-313-371(294,390)351-84-18-141(331-103(84)45-265)259-69-215-149-159(259)225-179(203)231-173(149)275)359-378(301,397)320-54-112-92(26-135(340-112)252-40-78(4)168(270)240-192(252)288)358-377(300,396)315-48-106-86(20-129(334-106)246-14-10-124(198)222-186(246)282)353-372(295,391)318-52-110-90(24-133(338-110)250-38-76(2)166(268)238-190(250)286)356-376(299,395)316-49-107-88(22-131(335-107)248-16-12-126(200)224-188(248)284)355-374(297,393)326-60-118-98(32-142(346-118)260-70-216-150-160(260)226-180(204)232-174(150)276)365-383(306,402)317-50-108-87(21-130(336-108)247-15-11-125(199)223-187(247)283)354-373(296,392)319-53-111-95(29-138(339-111)255-43-81(7)171(273)243-195(255)291)362-381(304,400)328-62-120-102(36-146(348-120)264-74-220-154-164(264)230-184(208)236-178(154)280)369-388(311,407)330-64-122-100(34-144(350-122)262-72-218-152-162(262)228-182(206)234-176(152)278)367-385(308,404)324-58-116-96(30-139(344-116)256-44-82(8)172(274)244-196(256)292)363-382(305,401)327-61-119-101(35-145(347-119)263-73-219-153-163(263)229-183(207)235-177(153)279)368-387(310,406)325-59-117-97(31-140(345-117)258-68-214-148-156(202)210-66-212-158(148)258)364-386(309,405)329-63-121-99(33-143(349-121)261-71-217-151-161(261)227-181(205)233-175(151)277)366-384(307,403)323-57-115-94(28-137(343-115)254-42-80(6)170(272)242-194(254)290)361-380(303,399)322-56-114-93(27-136(342-114)253-41-79(5)169(271)241-193(253)289)360-379(302,398)321-55-113-91(25-134(341-113)251-39-77(3)167(269)239-191(251)287)357-375(298,394)314-47-105-85(19-128(333-105)245-13-9-123(197)221-185(245)281)352-370(293,389)312-46-104-83(266)17-127(332-104)257-67-213-147-155(201)209-65-211-157(147)257/h9-16,37-44,65-74,83-122,127-146,265-266H,17-36,45-64H2,1-8H3,(H,293,389)(H,294,390)(H,295,391)(H,296,392)(H,297,393)(H,298,394)(H,299,395)(H,300,396)(H,301,397)(H,302,398)(H,303,399)(H,304,400)(H,305,401)(H,306,402)(H,307,403)(H,308,404)(H,309,405)(H,310,406)(H,311,407)(H2,197,221,281)(H2,198,222,282)(H2,199,223,283)(H2,200,224,284)(H2,201,209,211)(H2,202,210,212)(H,237,267,285)(H,238,268,286)(H,239,269,287)(H,240,270,288)(H,241,271,289)(H,242,272,290)(H,243,273,291)(H,244,274,292)(H3,203,225,231,275)(H3,204,226,232,276)(H3,205,227,233,277)(H3,206,228,234,278)(H3,207,229,235,279)(H3,208,230,236,280)/t83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,370?,371?,372?,373?,374?,375?,376?,377?,378?,379?,380?,381?,382?,383?,384?,385?,386?,387?,388?/m0/s1
InChI Key NMYKBZSMOUFOJV-FJSWQEPZSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Dean NM, McKay R, Condon TP, Bennett CF. (1994)
Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.
J Biol Chem, 269 (23): 16416-24. [PMID:7911467]
2. Kelland L. (2006)
Discontinued drugs in 2005: oncology drugs.
Expert Opin Investig Drugs, 15 (11): 1309-18. [PMID:17040193]
3. Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson PM, Obasaju CK et al.. (2006)
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
J Clin Oncol, 24 (9): 1428-34. [PMID:16549837]